e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Asthma and allergy: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study.
J. Stril (Dorval, QC, Canada)
Source:
International Congress 2017 – Asthma and allergy: from the bench to the bedside
Session:
Asthma and allergy: from the bench to the bedside
Session type:
Poster Discussion
Number:
3542
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Stril (Dorval, QC, Canada). Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study.. 3542
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis
Source: Virtual Congress 2020 – Management of allergy, asthma and COPD
Year: 2020
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
The eXpeRience registry: Monitoring the ‘real-world‘ effectiveness of omalizumab in allergic asthma
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands
Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care
Year: 2007
Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
Source: International Congress 2017 – Asthma management
Year: 2017
Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting
Source: International Congress 2017 – Asthma management
Year: 2017
Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011
Cost effectiveness of omalizumab in Swedish asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 441s
Year: 2006
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
A population-based clinical study of allergic and non-allergic asthma
Source: Annual Congress 2008 - Markers and triggers of asthma
Year: 2008
A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept